| Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial MC Garassino, O Martelli, M Broggini, G Farina, S Veronese, E Rulli, ... The lancet oncology 14 (10), 981-988, 2013 | 591 | 2013 |
| Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade G Lo Russo, M Moro, M Sommariva, V Cancila, M Boeri, G Centonze, ... Clinical Cancer Research 25 (3), 989-999, 2019 | 419 | 2019 |
| Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated … G Fucà, G Galli, M Poggi, GL Russo, C Proto, M Imbimbo, R Ferrara, ... ESMO open 4 (1), e000457, 2019 | 188 | 2019 |
| Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out C Proto, R Ferrara, D Signorelli, GL Russo, G Galli, M Imbimbo, A Prelaj, ... Cancer Treatment Reviews 75, 39-51, 2019 | 156 | 2019 |
| Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations F Ricci, F Bizzaro, M Cesca, F Guffanti, M Ganzinelli, A Decio, C Ghilardi, ... Cancer research 74 (23), 6980-6990, 2014 | 144 | 2014 |
| Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC M Moro, E Caiola, M Ganzinelli, E Zulato, E Rulli, M Marabese, ... Journal of Thoracic Oncology 13 (11), 1692-1704, 2018 | 96 | 2018 |
| KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy oncotarget, 2015 | 94 | 2015 |
| Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review A Prelaj, V Miskovic, M Zanitti, F Trovo, C Genova, G Viscardi, SE Rebuzzi, ... Annals of Oncology 35 (1), 29-65, 2024 | 91 | 2024 |
| EPSILoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort A Prelaj, R Ferrara, SE Rebuzzi, C Proto, D Signorelli, G Galli, A De Toma, ... Cancers 11 (12), 1954, 2019 | 72 | 2019 |
| Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer G Galli, T Triulzi, C Proto, D Signorelli, M Imbimbo, M Poggi, G Fucà, ... Lung Cancer 132, 72-78, 2019 | 70 | 2019 |
| Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer G Galli, A De Toma, F Pagani, G Randon, B Trevisan, A Prelaj, R Ferrara, ... Lung Cancer 137, 38-42, 2019 | 69 | 2019 |
| Treatment of lung large cell neuroendocrine carcinoma G Lo Russo, S Pusceddu, C Proto, M Macerelli, D Signorelli, M Vitali, ... Tumor Biology 37, 7047-7057, 2016 | 67 | 2016 |
| Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program A Prelaj, A Bottiglieri, C Proto, GL Russo, D Signorelli, R Ferrara, G Galli, ... European Journal of Cancer 149, 235-248, 2021 | 57 | 2021 |
| Triple negative breast cancers have a reduced expression of DNA repair genes E Ribeiro, M Ganzinelli, D Andreis, R Bertoni, R Giardini, SB Fox, ... PLoS One 8 (6), e66243, 2013 | 56 | 2013 |
| Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype F Ricci, S Bernasconi, P Perego, M Ganzinelli, G Russo, F Bono, ... Cell cycle 11 (10), 1966-1976, 2012 | 54 | 2012 |
| Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial E Rulli, M Marabese, V Torri, G Farina, S Veronese, A Bettini, F Longo, ... Annals of Oncology 26 (10), 2079-2084, 2015 | 51 | 2015 |
| Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil M Ganzinelli, L Carrassa, F Crippa, M Tavecchio, M Broggini, G Damia Clinical Cancer Research 14 (16), 5131-5141, 2008 | 51 | 2008 |
| Diagnosis and management of typical and atypical lung carcinoids S Pusceddu, GL Russo, M Macerelli, C Proto, M Vitali, D Signorelli, ... Critical Reviews in Oncology/Hematology 100, 167-176, 2016 | 50 | 2016 |
| Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases GL Russo, M Imbimbo, G Corrao, C Proto, D Signorelli, M Vitali, ... Oncotarget 8 (35), 59889, 2017 | 46 | 2017 |
| Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations M Ganzinelli, P Mariani, D Cattaneo, R Fossati, R Fruscio, S Corso, ... European journal of cancer 47 (7), 1086-1094, 2011 | 45 | 2011 |
